A Phase 3 interventional study of TV-46000 and Placebo in Schizophrenia, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 81 sites in 2 countries. Open to participants aged 13 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-03-10.
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies testing risperidone in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. Risperidone · Schizophrenia.
Among the 127 studies testing risperidone in Schizophrenia, this one is the 8th largest by enrollment of the 123 interventional ones that give a count, is one of 5 that started in 2018, is one of 34 in phase 3, and was the 109th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →4 of the 127 studies testing risperidone in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Northwell Health · Sites in United States, Canada
Ages 18–35
Louisiana State University Health Sciences Center Shreveport · Sites in United States
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
By country, each count listing its studies:
Risperidone: first FDA approval 1993 (RISPERDAL), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 13 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 7 · Phase 3 34 · Phase 4 63
First in 1996; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 544 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 100 across the 123 interventional studies. Of the 106 that completed or were terminated, 30 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
63 of 127 have an industry lead sponsor. The 10 most frequent:
This study is registered under Teva Branded Pharmaceutical Products R&D, Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Branded Pharmaceutical Products R&D, Inc. is the lead sponsor of 206 studies on the registry; none are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 47 (96%) have results posted.
Teva Pharmaceutical Industries, Ltd. has 9 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
2 of the studies testing risperidone in Schizophrenia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06482554Phase 3Louisiana State University Health Sciences Center ShreveportLumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | 2026-12 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 127 studies testing risperidone in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the efficacy, safety, and tolerability of different dose regimens of TV-46000 administered subcutaneously (SC) as compared to placebo during maintenance treatment in adult and adolescent participants with schizophrenia. The study will include male and female participants, 13 to 65 years of age, who have a confirmed diagnosis of schizophrenia, are clinically stable, and are eligible for risperidone treatment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The participant, if adult or adolescent male, is surgically sterile, or, if capable of producing offspring, or has exclusively same-sex partners or is currently using an approved method of birth control and agrees to the continued use of this method for the duration of the study (and for 120 days after the last dose of study drug). Male participants with sex partners who are women of childbearing potential must use condoms even if surgically sterile
Exclusion Criteria:
The participant has used an drug within 3 months prior to screening or has participated in a non-drug clinical trial within 30 days prior to screening.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive an SC injection of placebo matching to TV-46000 at baseline and every 4 weeks (q4w) thereafter. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.
Drug: Placebo
Participants will receive an SC injection of TV-46000 at baseline and q4w thereafter. The maximal dose for adult participants is comparable to an oral risperidone dose of 5 milligrams (mg)/day, and the maximal dose for adolescents is comparable to 4 mg/day. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.
Drug: TV-46000
Participants will receive an SC injection of TV-46000 at baseline and every 8 weeks (q8w) thereafter, and a placebo SC injection 4 weeks after baseline and q8w thereafter. The maximal dose for adult participants is comparable to an oral risperidone dose of 5 mg/day, and the maximal dose for adolescents is comparable to 4 mg/day. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.
Drug: TV-46000 · Drug: Placebo
TV-46000 will be administered per dose and schedule specified in the arm.
Also known as: Risperidone
Placebo matching to TV-46000 will be administered per schedule specified in the arm.
Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set
Relapse was defined as 1 or more of the following items: • Clinical Global Impression-Improvement (CGI-I) of ≥5, and - an increase of any of the 4 Positive and Negative Syndrome Scale (PANSS) items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of \>4 with an absolute increase of ≥2 on specific item since randomization, or - an increase in any of the 4 individual PANSS items to a score of \>4 and an absolute increase of ≥4 on combined score of 4 items since randomization; • hospitalization due to worsening of psychotic symptoms; • Clinical Global Impression-Severity of Suicidality (CGI-SS) of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2; • violent behavior resulting in clinically significant self-injury, injury to another person, or property damage. Data is presented as distribution of relapsing participants (number of participants with impending relapse).
Time frame: From randomization up to 108 weeks
Time to Impending Relapse (Number of Participants With Impending Relapse) for Extended ITT [eITT] Analysis Set
Relapse was defined as 1 or more of the following items: • CGI-I of ≥5, and - an increase of any of the 4 PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of \>4 with an absolute increase of ≥2 on specific item since randomization, or - an increase in any of the 4 individual PANSS items to a score of \>4 and an absolute increase of ≥4 on combined score of 4 items since randomization; • hospitalization due to worsening of psychotic symptoms; • CGI-SS of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2; • violent behavior resulting in clinically significant self-injury, injury to another person, or property damage. Data is presented as distribution of relapsing participants (adults and adolescents) (number of participants with impending relapse).
Time frame: From randomization up to 108 weeks
Proportion of Participants With Impending Relapse
Relapse was defined as 1 or more of the following items: • CGI-I of ≥5, and - an increase of any of the 4 PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of \>4 with an absolute increase of ≥2 on specific item since randomization, or - an increase in any of the 4 individual PANSS items to a score of \>4 and an absolute increase of ≥4 on combined score of 4 items since randomization; • hospitalization due to worsening of psychotic symptoms; • CGI-SS of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2; • violent behavior resulting in clinically significant self-injury, injury to another person, or property damage. Impending relapse rate at Week 24 was estimated using the Kaplan-Meier product estimate.
Time frame: Week 24
Number of Participants Who Maintain Stability at the Endpoint
Stability is defined as meeting all of the following criteria for at least 4 consecutive weeks: outpatient status; PANSS total score ≤80; minimal presence of specific psychotic symptoms on the PANSS, as measured by a score of ≤4 on each of the following items: conceptual disorganization, suspiciousness, hallucinatory behavior, and unusual thought content; Clinical Global Impression of Severity (CGI-S) score ≤4 (moderately ill); and CGI-SS score ≤2 (mildly suicidal) on Part 1 and ≤5 (minimally worsened) on Part 2. The last valid participant assessment was used as the endpoint.
Time frame: At the endpoint (up to 108 weeks)
Number of Participants Achieving Remission at the Endpoint
The remission was achieved for participants who did not relapse during the study and for over a period of at least 6 months preceding the endpoint, maintained scores of = 3 on each of the 8 specific PANSS items: P1 (delusions), G9 (unusual thought content), P3 (hallucinatory behavior), P2 (conceptual disorganization), G5 (mannerisms/posturing), N1 (blunted affect), N4 (social withdrawal), and N6 (lack of spontaneity). The last valid participant assessment was used as the endpoint.
Time frame: At Endpoint (up to 108 weeks)
Observed Rate of Impending Relapse (Number of Participants With Impending Relapse) at the Endpoint
Relapse was defined as 1 or more of the following items: • CGI-I of ≥5, and - an increase of any of the 4 PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of \>4 with an absolute increase of ≥2 on specific item since randomization, or - an increase in any of the 4 individual PANSS items to a score of \>4 and an absolute increase of ≥4 on combined score of 4 items since randomization; • hospitalization due to worsening of psychotic symptoms; • CGI-SS of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2; • violent behavior resulting in clinically significant self-injury, injury to another person, or property damage. Observed rate of impending relapse was calculated as the number of participants who relapsed by endpoint divided by the number of participants in each treatment group, using the last valid participant assessment as the endpoint.
Time frame: At the Endpoint (up to 108 weeks)
Time to Impending Relapse (Number of Participants With Impending Relapse) in the Adolescent Participants
Relapse was defined as 1 or more of the following items: • CGI-I of ≥5, and - an increase of any of the 4 PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of \>4 with an absolute increase of ≥2 on specific item since randomization, or - an increase in any of the 4 individual PANSS items to a score of \>4 and an absolute increase of ≥4 on combined score of 4 items since randomization; • hospitalization due to worsening of psychotic symptoms; • CGI-SS of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2; • violent behavior resulting in clinically significant self-injury, injury to another person, or property damage. Data is presented as distribution of relapsing participants (adolescents) (number of participants with impending relapse).
Time frame: From randomization up to 108 weeks
Change From Baseline in Drug Attitudes Inventory 10-item Version (DAI-10) Total Score at the Endpoint and End of Treatment
The DAI-10 is a 10-item questionnaire to assess 1) subjective experience of drug and 2) attitudes and beliefs toward neuroleptics which may influence compliance in schizophrenia participants. The DAI-10 contains 6 items (1, 3, 4, 7, 9, and 10) that a participant who was fully adherent to the prescribed medication answered as "True" and 4 items (2, 5, 6, and 8) that a participant who was fully adherent to the prescribed medication answered as "False." A correct answer was scored +1 and an incorrect answer was scored -1. The total score was the sum of pluses and minuses, which ranged from -10 to 10 in increments of 2. A positive total score indicated a positive subjective response (compliant) and a negative total score indicated a negative subjective response (non-compliance). Higher scores denoted better compliance. The last valid participant assessment was used as the endpoint.
Time frame: Baseline, endpoint and end of treatment (up to Week 108)
Change From Baseline in Schizophrenia Quality of Life Scale (SQLS) Total Score at the Endpoint and End of Treatment
The SQLS comprises 33 items categorized in 2 domains: psychosocial feelings (20 items) and cognition and vitality (13 items). The items were scored on a 5-point scale (1 - never, 2 - rarely, 3 - sometimes, 4 - often, 5 - always). Individual domain and total scores were standardized by scoring algorithm to a 0 (best health status) to 100 (worst health status) scale, with higher scores indicating comparatively lower quality of life. The last valid participant assessment was used as the endpoint.
Time frame: Baseline, endpoint and end of treatment (up to Week 108)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were defined as AEs occurring after the first dose of the study drug until 120 days after the last dose of study drug. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
Time frame: From randomization up to 120 days after last dose of study drug (up to Week 125)
Change From Baseline in Total Abnormal Involuntary Movement Scale (AIMS) Score at the End of Treatment
The AIMS is a 14-item scale that includes assessments of orofacial movements, extremity and truncal dyskinesia, examiner's judgment of global severity, subjective measures of awareness of movements and distress, and a yes/no assessment of problems concerning teeth and/or dentures. Total AIMS score is a sum of item 1 through 7. Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 0 (no dyskinesia) to 4 (severe dyskinesia) scale. Total AIMS score for Items 1-7 ranged from 0 to 28; with higher scores indicating greater severity of the condition.
Time frame: Baseline, end of treatment (up to 108 weeks)
Change From Baseline in Simpson-Angus Scale (SAS) Mean Score at the End of Treatment
The SAS is a 10-item instrument for the assessment of neuroleptic-induced parkinsonism. The items on the scale include measurements of hypokinesia, rigidity, glabellar reflex, tremor, and salivation. Each item was rated on a 5-point scale (0 \[None/Normal\] to 4 \[Extreme/Severe\]). The mean score was calculated by adding the individual item scores and dividing by 10. The total mean score ranged from 0-4, with a higher score indicating greater severity of symptoms.
Time frame: Baseline, end of treatment (up to 108 weeks)
Change From Baseline in Total Barnes Akathisia Rating Scale (BARS) Score at the End of Treatment
The BARS is an instrument that assesses the severity of drug-induced akathisia. The BARS includes 3 items for rating objective restless movements, subjective restlessness, and any subjective distress associated with akathisia that were scored on a 4-point scale of 0 (normal/no distress) to 3 (constant restlessness/severe distress). Total score was the sum of scores of each item and ranged from 0-9, with higher scores indicating greater severity of akathisia.
Time frame: Baseline, end of treatment (up to 108 weeks)
Number of Participants Reporting Suicidal Behavior and Suicidal Ideation Using Columbia-Suicide Severity Rating Scale (C-SSRS) at Baseline and Post-Baseline
The C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior was defined as a "yes" answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation was defined as a "yes" answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation.
Time frame: Baseline, post-baseline (up to 108 weeks)
Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Score at the End of Treatment
The CDSS is specifically designed to assess the level of depression separate from the positive, negative, and EPS in schizophrenia. This clinician-administered instrument consists of 9 items, each rated on a 4-point scale from 0 (absent) to 3 (severe) that were added together to form the total CDSS depression score of the participant. The total score ranged from 0-27, with higher scores indicating greater severity of the condition.
Time frame: Baseline, end of treatment (up to 108 weeks)
Change From Baseline in Clinical Global Impression-Severity of Suicidality (CGI-SS) Score at the End of Treatment
The CGI-SS scale provides an overall clinician-rated assessment of the risk of suicidality. The CGI-SS consists of a 5-point scale in Part 1 (the most severe level of suicidality experience) ranging from 1 (not at all suicidal) to 5 (attempted suicide) and a 7-point scale in Part 2 (change in participant suicidality) ranging from 1 (very much improved) to 7 (very much worse).
Time frame: Baseline, end of treatment (up to 108 weeks)
Plasma Concentration of Risperidone, 9-OH-risperidone, and Total Active Moiety (Sum of Risperidone and 9-OH-risperidone)
Time frame: 1 hour prior to dosing at Baseline (Day 1) and at the end of treatment visit (up to 108 weeks)
| Milestone | Placebo | TV-46000 q1m | TV-46000 q2m |
|---|---|---|---|
| Started | 181 | 183 | 180 |
| Received at least 1 dose of study drug | 179 | 183 | 180 |
| Completed | 142 | 144 | 140 |
| Not completed | 39 | 39 | 40 |
| Withdrew: Death | 1 | 0 | 4 |
| Withdrew: Adverse event | 3 | 4 | 2 |
| Withdrew: Withdrawal by subject | 12 | 17 | 16 |
| Withdrew: Protocol violation | 5 | 0 | 3 |
| Withdrew: Lost to follow-up | 17 | 15 | 12 |
| Withdrew: Other than specified | 1 | 3 | 3 |
Relapse was defined as 1 or more of the following items: • Clinical Global Impression-Improvement (CGI-I) of ≥5, and - an increase of any of the 4 Positive and Negative Syndrome Scale (PANSS) items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of \>4 with an absolute increase of ≥2 on specific item since randomization, or - an increase in any of the 4 individual PANSS items to a score of \>4 and an absolute increase of ≥4 on combined score of 4 items since randomization; • hospitalization due to worsening of psychotic symptoms; • Clinical Global Impression-Severity of Suicidality (CGI-SS) of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2; • violent behavior resulting in clinically significant self-injury, injury to another person, or property damage. Data is presented as distribution of relapsing participants (number of participants with impending relapse).
| Participants | Placebo | TV-46000 q1m | TV-46000 q2m |
|---|---|---|---|
| Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set | 53 | 13 | 23 |
Relapse was defined as 1 or more of the following items: • CGI-I of ≥5, and - an increase of any of the 4 PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of \>4 with an absolute increase of ≥2 on specific item since randomization, or - an increase in any of the 4 individual PANSS items to a score of \>4 and an absolute increase of ≥4 on combined score of 4 items since randomization; • hospitalization due to worsening of psychotic symptoms; • CGI-SS of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2; • violent behavior resulting in clinically significant self-injury, injury to another person, or property damage. Data is presented as distribution of relapsing participants (adults and adolescents) (number of participants with impending relapse).
| Participants | Placebo | TV-46000 q1m | TV-46000 q2m |
|---|---|---|---|
| Time to Impending Relapse (Number of Participants With Impending Relapse) for Extended ITT [eITT] Analysis Set | 53 | 13 | 24 |
Relapse was defined as 1 or more of the following items: • CGI-I of ≥5, and - an increase of any of the 4 PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of \>4 with an absolute increase of ≥2 on specific item since randomization, or - an increase in any of the 4 individual PANSS items to a score of \>4 and an absolute increase of ≥4 on combined score of 4 items since randomization; • hospitalization due to worsening of psychotic symptoms; • CGI-SS of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2; • violent behavior resulting in clinically significant self-injury, injury to another person, or property damage. Impending relapse rate at Week 24 was estimated using the Kaplan-Meier product estimate.
| proportion of participants | Placebo | TV-46000 q1m | TV-46000 q2m |
|---|---|---|---|
| Proportion of Participants With Impending Relapse | 0.28 (0.205 to 0.347) | 0.07 (0.03 to 0.109) | 0.11 (0.065 to 0.165) |
Stability is defined as meeting all of the following criteria for at least 4 consecutive weeks: outpatient status; PANSS total score ≤80; minimal presence of specific psychotic symptoms on the PANSS, as measured by a score of ≤4 on each of the following items: conceptual disorganization, suspiciousness, hallucinatory behavior, and unusual thought content; Clinical Global Impression of Severity (CGI-S) score ≤4 (moderately ill); and CGI-SS score ≤2 (mildly suicidal) on Part 1 and ≤5 (minimally worsened) on Part 2. The last valid participant assessment was used as the endpoint.
| Participants | Placebo | TV-46000 q1m | TV-46000 q2m |
|---|---|---|---|
| Number of Participants Who Maintain Stability at the Endpoint | 110 | 159 | 143 |
The remission was achieved for participants who did not relapse during the study and for over a period of at least 6 months preceding the endpoint, maintained scores of = 3 on each of the 8 specific PANSS items: P1 (delusions), G9 (unusual thought content), P3 (hallucinatory behavior), P2 (conceptual disorganization), G5 (mannerisms/posturing), N1 (blunted affect), N4 (social withdrawal), and N6 (lack of spontaneity). The last valid participant assessment was used as the endpoint.
| Participants | Placebo | TV-46000 q1m | TV-46000 q2m |
|---|---|---|---|
| Number of Participants Achieving Remission at the Endpoint | 30 | 39 | 42 |
Relapse was defined as 1 or more of the following items: • CGI-I of ≥5, and - an increase of any of the 4 PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of \>4 with an absolute increase of ≥2 on specific item since randomization, or - an increase in any of the 4 individual PANSS items to a score of \>4 and an absolute increase of ≥4 on combined score of 4 items since randomization; • hospitalization due to worsening of psychotic symptoms; • CGI-SS of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2; • violent behavior resulting in clinically significant self-injury, injury to another person, or property damage. Observed rate of impending relapse was calculated as the number of participants who relapsed by endpoint divided by the number of participants in each treatment group, using the last valid participant assessment as the endpoint.
| Participants | Placebo | TV-46000 q1m | TV-46000 q2m |
|---|---|---|---|
| Observed Rate of Impending Relapse (Number of Participants With Impending Relapse) at the Endpoint | 53 | 13 | 23 |
Relapse was defined as 1 or more of the following items: • CGI-I of ≥5, and - an increase of any of the 4 PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of \>4 with an absolute increase of ≥2 on specific item since randomization, or - an increase in any of the 4 individual PANSS items to a score of \>4 and an absolute increase of ≥4 on combined score of 4 items since randomization; • hospitalization due to worsening of psychotic symptoms; • CGI-SS of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2; • violent behavior resulting in clinically significant self-injury, injury to another person, or property damage. Data is presented as distribution of relapsing participants (adolescents) (number of participants with impending relapse).
| Participants | Placebo | TV-46000 q1m | TV-46000 q2m |
|---|---|---|---|
| Time to Impending Relapse (Number of Participants With Impending Relapse) in the Adolescent Participants | — | — | 1 |
The DAI-10 is a 10-item questionnaire to assess 1) subjective experience of drug and 2) attitudes and beliefs toward neuroleptics which may influence compliance in schizophrenia participants. The DAI-10 contains 6 items (1, 3, 4, 7, 9, and 10) that a participant who was fully adherent to the prescribed medication answered as "True" and 4 items (2, 5, 6, and 8) that a participant who was fully adherent to the prescribed medication answered as "False." A correct answer was scored +1 and an incorrect answer was scored -1. The total score was the sum of pluses and minuses, which ranged from -10 to 10 in increments of 2. A positive total score indicated a positive subjective response (compliant) and a negative total score indicated a negative subjective response (non-compliance). Higher scores denoted better compliance. The last valid participant assessment was used as the endpoint.
| units on a scale | Placebo | TV-46000 q1m | TV-46000 q2m |
|---|---|---|---|
| Baseline | 6.1 ± 3.23 | 5.8 ± 3.63 | 5.7 ± 3.13 |
| Change at the Endpoint | -0.8 ± 3.88 | 0.1 ± 3.34 | -0.3 ± 3.65 |
| Change at the End of Treatment | -0.9 ± 3.42 | 0.3 ± 2.84 | 0.3 ± 3.51 |
The SQLS comprises 33 items categorized in 2 domains: psychosocial feelings (20 items) and cognition and vitality (13 items). The items were scored on a 5-point scale (1 - never, 2 - rarely, 3 - sometimes, 4 - often, 5 - always). Individual domain and total scores were standardized by scoring algorithm to a 0 (best health status) to 100 (worst health status) scale, with higher scores indicating comparatively lower quality of life. The last valid participant assessment was used as the endpoint.
| units on a scale | Placebo | TV-46000 q1m | TV-46000 q2m |
|---|---|---|---|
| Baseline | 34.0 ± 16.06 | 33.1 ± 16.79 | 34.2 ± 15.70 |
| Change at the Endpoint | 0.9 ± 14.24 | -4.5 ± 14.31 | -4.1 ± 15.23 |
| Change at the End of Treatment | -2.3 ± 13.26 | -7.2 ± 13.79 | -7.3 ± 12.30 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were defined as AEs occurring after the first dose of the study drug until 120 days after the last dose of study drug. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
| Participants | Placebo | TV-46000 q1m | TV-46000 q2m |
|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 92 | 111 | 121 |
The AIMS is a 14-item scale that includes assessments of orofacial movements, extremity and truncal dyskinesia, examiner's judgment of global severity, subjective measures of awareness of movements and distress, and a yes/no assessment of problems concerning teeth and/or dentures. Total AIMS score is a sum of item 1 through 7. Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 0 (no dyskinesia) to 4 (severe dyskinesia) scale. Total AIMS score for Items 1-7 ranged from 0 to 28; with higher scores indicating greater severity of the condition.
| units on a scale | Placebo | TV-46000 q1m | TV-46000 q2m |
|---|---|---|---|
| Baseline | 0.4 ± 1.30 | 0.5 ± 1.83 | 0.2 ± 0.79 |
| Change at the End of Treatment | 0.0 ± 1.10 | 0.1 ± 0.62 | 0.1 ± 1.00 |
The SAS is a 10-item instrument for the assessment of neuroleptic-induced parkinsonism. The items on the scale include measurements of hypokinesia, rigidity, glabellar reflex, tremor, and salivation. Each item was rated on a 5-point scale (0 \[None/Normal\] to 4 \[Extreme/Severe\]). The mean score was calculated by adding the individual item scores and dividing by 10. The total mean score ranged from 0-4, with a higher score indicating greater severity of symptoms.
| units on a scale | Placebo | TV-46000 q1m | TV-46000 q2m |
|---|---|---|---|
| Baseline | 0.07 ± 0.137 | 0.09 ± 0.195 | 0.06 ± 0.134 |
| Change at the End of Treatment | 0.04 ± 0.134 | 0.02 ± 0.211 | 0.00 ± 0.102 |
The BARS is an instrument that assesses the severity of drug-induced akathisia. The BARS includes 3 items for rating objective restless movements, subjective restlessness, and any subjective distress associated with akathisia that were scored on a 4-point scale of 0 (normal/no distress) to 3 (constant restlessness/severe distress). Total score was the sum of scores of each item and ranged from 0-9, with higher scores indicating greater severity of akathisia.
| units on a scale | Placebo | TV-46000 q1m | TV-46000 q2m |
|---|---|---|---|
| Baseline | 0.2 ± 0.63 | 0.1 ± 0.39 | 0.2 ± 0.57 |
| Change at the End of Treatment | -0.1 ± 0.56 | 0.0 ± 0.51 | -0.1 ± 0.56 |
The C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior was defined as a "yes" answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation was defined as a "yes" answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation.
| Participants | Placebo | TV-46000 q1m | TV-46000 q2m |
|---|---|---|---|
| Baseline: Suicidal behavior | 0 | 0 | 3 |
| Baseline: Suicidal ideation | 6 | 5 | 7 |
| Post-baseline: Suicidal behavior | 3 | 1 | 1 |
| Post-baseline: Suicidal ideation | 12 | 7 | 12 |
The CDSS is specifically designed to assess the level of depression separate from the positive, negative, and EPS in schizophrenia. This clinician-administered instrument consists of 9 items, each rated on a 4-point scale from 0 (absent) to 3 (severe) that were added together to form the total CDSS depression score of the participant. The total score ranged from 0-27, with higher scores indicating greater severity of the condition.
| units on a scale | Placebo | TV-46000 q1m | TV-46000 q2m |
|---|---|---|---|
| Baseline | 1.6 ± 2.14 | 1.3 ± 1.92 | 1.5 ± 1.93 |
| Change at the End of Treatment | -0.4 ± 2.72 | -0.3 ± 1.39 | -0.8 ± 2.24 |
The CGI-SS scale provides an overall clinician-rated assessment of the risk of suicidality. The CGI-SS consists of a 5-point scale in Part 1 (the most severe level of suicidality experience) ranging from 1 (not at all suicidal) to 5 (attempted suicide) and a 7-point scale in Part 2 (change in participant suicidality) ranging from 1 (very much improved) to 7 (very much worse).
| units on a scale | Placebo | TV-46000 q1m | TV-46000 q2m |
|---|---|---|---|
| The most severe level of suicidality experience at Baseline | 1.0 ± 0.00 | 1.0 ± 0.00 | 1.0 ± 0.00 |
| Change in participant suicidality at the End of Treatment | 4.0 ± 0.00 | 4.0 ± 0.00 | 4.0 ± 0.00 |
| ng/mL | Placebo | TV-46000 q1m | TV-46000 q2m |
|---|---|---|---|
| Risperidone at Baseline | 4.694 (0.050 to 58.376) | 6.452 (0.050 to 97.935) | 5.364 (0.05 to 125.524) |
| Risperidone at the End of Treatment | 1.323 (0.050 to 47.683) | 13.215 (0.050 to 136.184) | 8.838 (0.05 to 75.95) |
| 9-OH-Risperidone at Baseline | 14.965 (0.150 to 84.471) | 18.473 (0.15 to 105.26) | 15.187 (0.15 to 107.316) |
| 9-OH-Risperidone at the End of Treatment | 2.982 (0.150 to 40.730) | 26.202 (0.15 to 101.354) | 17.778 (0.15 to 88.333) |
| Total Active Moiety at Baseline | 19.060 (0.050 to 95.595) | 24.200 (0.050 to 134.202) | 19.945 (0.05 to 172.763) |
| Total Active Moiety at the End of Treatment | 4.078 (0.050 to 62.621) | 38.429 (0.050 to 159.498) | 25.947 (0.05 to 135.823) |
Collected over From randomization up to 120 days after last dose of study drug (up to Week 125). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 1/179 (0.6%) | 14/179 (7.8%) | 35/179 (19.6%) |
| TV-46000 q1m | 0/183 (0%) | 8/183 (4.4%) | 49/183 (26.8%) |
| TV-46000 q2m | 4/180 (2.2%) | 10/180 (5.6%) | 48/180 (26.7%) |
| Event | Placebo | TV-46000 q1m | TV-46000 q2m |
|---|---|---|---|
| SchizophreniaPsychiatric disorders | 4/179 | 0/183 | 2/180 |
| Pelvic abscessInfections and infestations | 0/71 | 1/71 | 0/70 |
| Psychotic disorderPsychiatric disorders | 2/179 | 0/183 | 1/180 |
| Psychotic symptomPsychiatric disorders | 2/179 | 0/183 | 0/180 |
| Suicidal ideationPsychiatric disorders | 1/179 | 2/183 | 0/180 |
| Myocardial infarctionCardiac disorders | 1/179 | 0/183 | 0/180 |
| Pancreatitis acuteGastrointestinal disorders | 1/179 | 0/183 | 0/180 |
| CholelithiasisHepatobiliary disorders | 1/179 | 0/183 | 0/180 |
| PneumoniaInfections and infestations | 1/179 | 0/183 | 0/180 |
| SyncopeNervous system disorders | 1/179 | 0/183 | 0/180 |
| Event | Placebo | TV-46000 q1m | TV-46000 q2m |
|---|---|---|---|
| Injection site noduleGeneral disorders | 6/179 | 12/183 | 13/180 |
| Weight increasedInvestigations | 6/179 | 10/183 | 13/180 |
| Injection site painGeneral disorders | 11/179 | 9/183 | 12/180 |
| InsomniaPsychiatric disorders | 10/179 | 12/183 | 5/180 |
| HeadacheNervous system disorders | 10/179 | 9/183 | 11/180 |
| Injection site pruritusGeneral disorders | 4/179 | 10/183 | 7/180 |
Extended intent-to-treat (eITT) analysis set included all participants (adults and adolescents) randomized to the double-blind maintenance stage treatment, regardless if they had received treatment or not.
| Age, Continuous(years) | Placebo | TV-46000 q1m | TV-46000 q2m | Total |
|---|---|---|---|---|
| Mean | 49.2 ± 11.43 | 50.6 ± 10.30 | 48.1 ± 11.09 | 49.3 ± 10.98 |
| Sex: Female, Male(Participants) | Placebo | TV-46000 q1m | TV-46000 q2m | Total |
|---|---|---|---|---|
| Female | 71 | 71 | 70 | 212 |
| Male | 110 | 112 | 110 | 332 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | TV-46000 q1m | TV-46000 q2m | Total |
|---|---|---|---|---|
| Hispanic or Latino | 42 | 39 | 36 | 117 |
| Not Hispanic or Latino | 139 | 144 | 144 | 427 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | TV-46000 q1m | TV-46000 q2m | Total |
|---|---|---|---|---|
| Race — White | 68 | 72 | 66 | 206 |
| Race — Black or African American | 104 | 108 | 110 | 322 |
| Race — Asian | 4 | 1 | 2 | 7 |
| Race — Native Hawaiian or Other Pacific Islander | 1 | 1 | 0 | 2 |
| Race — Not Reported | 2 | 1 | 0 | 3 |
| Race — Other | 2 | 0 | 2 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be reviewed for scientific merit, product approval status, and conflicts of interest. Patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.)
Ran from Apr 2018 to primary completion in Sep 2020, 29 months.
Results were first posted in Dec 2021, 1 year 2 months after primary completion.
Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 29 months is close to that.
Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Risperidone
Teva Branded Pharmaceutical Products R&D, Inc. →